Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LQDA | Restricted Stock Unit | Options Exercise | $0 | -15.8K | -100% | $0.00* | 0 | Jan 3, 2023 | Common Stock | 15.8K | Direct | F1 |
Id | Content |
---|---|
F1 | Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
F2 | On January 3, 2022, the Reporting Person was granted 63,230 RSUs (the "2022 RSUs") with 25% vesting quarterly through the first anniversary of the grant date. As of January 3, 2023, the 2022 RSUs have fully vested. |
F3 | The number of securities shown to be beneficially owned following the transaction being reported in this Form 4 reflects a downward adjustment of 15,808 shares of common stock due to a previous clerical error in double counting a vested portion of the 2022 RSUs in that certain previous Form 4 filed by the Reporting Person on October 4, 2022. |
F4 | The securities are held by Roger A. Jeffs Living Trust UAD 2/29/2000 (the "Trust"). The Reporting Person is the trustee of the Trust. |
F5 | The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. |